Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Goldschmidt

Showing results (411-420 of 539) with videos related to

Pageof 54
Sort By:
Immunotherapy|November 24, 2020
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparisonPhilippe Moreau, Benjamin Hebraud, Thierry Facon, et al.
Bone Marrow Transplantation|December 5, 2024
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myelomaNora Grieb, Alexander Oeser, Maximilian Ferle, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Blood|May 20, 2024
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myelomaOla Landgren, Thomas J Prior, Tara Masterson, et al.
Blood Cancer Journal|February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Blood|March 23, 2016
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working GroupPieter Sonneveld, Hervé Avet-Loiseau, Sagar Lonial, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
Haematologica|July 15, 2021
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. HydePellegrino Musto, Monika Engelhardt, Jo Caers, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Pageof 54

Showing results (411-420 of 539) with videos related to

Sort By:
Pageof 54
Immunotherapy|November 24, 2020
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparisonPhilippe Moreau, Benjamin Hebraud, Thierry Facon, et al.
Bone Marrow Transplantation|December 5, 2024
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myelomaNora Grieb, Alexander Oeser, Maximilian Ferle, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Mutagenic impact and evolutionary influence of radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Blood|May 20, 2024
EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myelomaOla Landgren, Thomas J Prior, Tara Masterson, et al.
Blood Cancer Journal|February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Blood|March 23, 2016
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working GroupPieter Sonneveld, Hervé Avet-Loiseau, Sagar Lonial, et al.
Haematologica|July 11, 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myelomaJesus F San Miguel, Katja C Weisel, Kevin W Song, et al.
Haematologica|July 15, 2021
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. HydePellegrino Musto, Monika Engelhardt, Jo Caers, et al.
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
Pageof 54